Kinnate Biopharma (Kinnate Biopharma) Financial Strength : 7 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kinnate Biopharma Financial Strength?

Kinnate Biopharma has the Financial Strength Rank of 7.

Good Sign:

Kinnate Biopharma Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Kinnate Biopharma's interest coverage with the available data. As of today, Kinnate Biopharma's Altman Z-Score is 0.00.

Competitive Comparison of Kinnate Biopharma's Financial Strength

For the Biotechnology subindustry, Kinnate Biopharma's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kinnate Biopharma's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kinnate Biopharma's Financial Strength distribution charts can be found below:

* The bar in red indicates where Kinnate Biopharma's Financial Strength falls into.

Kinnate Biopharma Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Kinnate Biopharma's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-19.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.28 Mil.

Kinnate Biopharma's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Kinnate Biopharma's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Kinnate Biopharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Kinnate Biopharma's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio	=	Total Debt (Q: Dec. 2023 )			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.892	+	2.283)	/	0
	=	N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Kinnate Biopharma has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kinnate Biopharma (NAS:KNTE) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Kinnate Biopharma has the Financial Strength Rank of 7.

Kinnate Biopharma Financial Strength Related Terms

Thank you for viewing the detailed overview of Kinnate Biopharma's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.

Kinnate Biopharma (Kinnate Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kinnate Biopharma Inc (NAS:KNTE) » Definitions » Financial Strength

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Montgomery Street, Suite 150, The Presidio of San Francisco, San Francisco, CA, USA, 94129

Website

https://www.kinnate.com

Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.

Executives

James B. Tananbaum	director, 10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Orbimed Asia Gp Iv, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY 10022
Orbimed Advisors Iv Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Viii Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Richard Thomas Williams	officer: Chief Medical Officer	C/O KINNATE BIOPHARMA INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Helen Sabzevari	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Neha Krishnamohan	officer: Chief Financial Officer	12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164